Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus

Amneal Reports Third Quarter 2020 Financial Results

November 6, 2020 6:00 AM EST

Q3 2020 Net Revenue of $519 million; GAAP Net Loss of $(9) million; Diluted Loss per Share of $(0.06)

Q3 2020 Adjusted Net Income (1) of $49 million; Adjusted EBITDA (1) of $114 million; Adjusted Diluted EPS (1) of $0.16

Updating 2020 Full Year Financial Outlook

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the Company) announced its results today for the third quarter ended September 30, 2020.

Amneal delivered another strong quarter, providing further evidence that our Amneal 2.0 strategy is positioning the company for sustained growth, said Chirag and Chintu... More